Blood levels of dual-specificity phosphatase-1 independently predict risk for post-operative morbidities causing prolonged hospitalization after coronary artery bypass grafting

International Journal of Molecular Medicine

Volumn 27, Issue 6, 2011, Pages 851-857

  Hägg, Sara ^a,d   Alserius, Thomas ^b   Noori, Peri ^a,c   Ruusalepp, Arno ^e   Ivert, Torbjörn ^b   Tegnér, Jesper ^c,d   Björkegren, Johan ^a,c,d,e   Skogsberg, Josefin ^a,c,d  

^a Cardiovascular Genomics Group   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Clinical Gene Networks AB   (Sweden)

^e UNIVERSITY OF TARTU   (Estonia)

Author keywords

Biological marker; Coronary artery disease; Dual specificity phosphatase 1; Gene expression profiling; Post operative stay

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1;

AGED; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DUSP1 GENE; ENZYME BLOOD LEVEL; FEMALE; GENE; GENE EXPRESSION PROFILING; GENOME; HOMEOSTASIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PLANNING; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL RISK; VALIDATION PROCESS;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; MALE; MIDDLE AGED; MORBIDITY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79954487848     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.650     Document Type: Article

References (32)

1. Schadt EE, Sachs A and Friend S: Embracing complexity, inching closer to reality. Sci STKE 2005: pe40, 2005.
2. Ouzounian M, Lee DS, Gramolini AO, Emili A, Fukuoka M and Liu PP: Predict, prevent and personalize: Genomic and proteomic approaches to cardiovascular medicine. Can J Cardiol 23 (Suppl A): 28A-33A, 2007.
3. Alserius T, Hammar N, Nordqvist T and Ivert T: Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. Am Heart J 152: 599-605, 2006.
4. Latham R, Lancaster AD, Covington JF, Pirolo JS and Thomas CS: The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 22: 607-612, 2001.
5. Pomposelli JJ, Baxter JK, III, Babineau TJ, et al: Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 22: 77-81, 1998.
6. Takamura T, Sakurai M, Ota T, Ando H, Honda M and Kaneko S: Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. Diabetologia 47: 638-647, 2004.
7. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM and Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87: 978-982, 2002.
8. Anderson RE, Klerdal K, Ivert T, Hammar N, Barr G and Owall A: Are even impaired fasting blood glucose levels preoperatively associated with increased mortality after CABG surgery? Eur Heart J 26: 1513-1518, 2005.
9. Hagg S, Skogsberg J, Lundstrom J, et al: Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet 5: e1000754, 2009.
10. Carlson K: Lipoprotein fractionation. J Clin Pathol Suppl (Assoc Clin Pathol) 5: 32-37, 1973.
11. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B and Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15, 2003.
12. Corsetti JP, Zareba W, Moss AJ and Sparks CE: Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 183: 293-300, 2005.
13. Szabo Z, Hakanson E and Svedjeholm R: Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 74: 712-719, 2002.
14. Issac TT, Dokainish H and Lakkis NM Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50: 2021-2028, 2007.
15. Liuba I, Ahlmroth H, Jonasson L, et al: Source of inflammatory markers in patients with atrial fibrillation. Europace 10: 848-853, 2008.
16. Kang JG, Patino WD, Matoba S and Hwang PM: Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med 16: 163-168, 2006.
17. Lang R, Hammer M and Mages J: DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 177: 7497-7504, 2006.
18. Ruel M, Bianchi C, Khan TA, et al: Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. J Thorac Cardiovasc Surg 126: 1521-1530, 2003.
19. Khan TA, Bianchi C, Ruel M, et al: Mitogen-activated protein kinase inhibition and cardioplegia-cardiopulmonary bypass reduce coronary myogenic tone. Circulation 108 (Suppl 1): 11348-11353, 2003.
20. Cowper PA, DeLong ER, Hannan EL, et al: Is early too early? Effect of shorter stays after bypass surgery. Ann Thorac Surg 83: 100-107, 2007.
21. Schalkwijk CG, Poland DC, van Dijk W, et al: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42: 351-357, 1999.
22. Kanter JE, Averill MM, Leboeuf RC and Bornfeldt KE: Diabetes-accelerated atherosclerosis and inflammation. Circ Res 103: e116-e117, 2008.
23. Fisman EZ, Adler Y and Tenenbaum A: Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol 45: 44-64, 2008.
24. Virani SS, Polsani VR and Nambi V: Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 10: 164-170, 2008.
25. Patino WD, Mian OY, Kang JG, et al: Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci USA 102: 3423-3428, 2005.
26. Alessi DR, Smythe C and Keyse SM: The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene 8: 2015-2020, 1993.
27. Abraham SM and Clark AR: Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34: 1018-1023, 2006.
28. Chi H, Barry SP, Roth RJ, et al: Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 103: 2274-2279, 2006.
29. Denkert C, Schmitt WD, Berger S, et al: Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 102: 507-513, 2002.
30. Tsujita E, Taketomi A, Gion T, et al: Suppressed MKP-1 is an independent predictor of outcome inpatients with hepatocellular carcinoma. Oncology 69: 342-347, 2005.
31. Khan TA, Bianchi C, Araujo EG et al: Cardiopulmonary bypass reduces peripheral microvascular contractile function by inhibition of mitogen-activated protein kinase activity. Surgery 134: 247-254, 2003.
32. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al: Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96: 3542-3548, 1997.